Zasocitinib(TAK-279)抑制酪氨酸激酶2治疗银屑病的随机临床试验
这项2b期随机双盲安慰剂对照试验评估了口服选择性TYK2抑制剂zasocitinib在中重度斑块状银屑病患者中的疗效与安全性。287例随机分组,259例接受治疗,每日一次2、5、15或30 mg或安慰剂共12周。第12周PASI 75应答率随剂量升高,5 mg及以上剂量优于安慰剂,安全性与安慰剂相当。
要点
- zasocitinib 5 mg及以上剂量每日一次治疗12周,PASI 75应答率高于安慰剂。
- 30 mg组PASI 100应答率达33%,呈现剂量效应。
- 治疗中出现的不良事件发生率与安慰剂相近,无剂量依赖性。
核心结论
- 口服zasocitinib 5 mg及以上剂量每日一次治疗12周,皮肤清除效果优于安慰剂。
研究设计与样本
- 2b期随机双盲安慰剂对照多剂量临床试验,2021年8月11日至2022年9月12日在美国47个中心和加拿大8个中心开展。
- 纳入18至70岁、PASI≥12、PGA≥3且斑块状银屑病体表面积≥10%的患者。
- 287例患者随机分配(1:1:1:1:1)至zasocitinib 2、5、15、30 mg或安慰剂口服每日一次治疗12周,259例(90.2%)至少接受一剂研究治疗。
主要发现
- 第12周PASI 75应答率:zasocitinib 2 mg组9例(18%)、5 mg组23例(44%)、15 mg组36例(68%)、30 mg组35例(67%),安慰剂组3例(6%)。
- PASI 90应答与PASI 75结果一致。
- PASI 100在所有剂量呈剂量效应,zasocitinib 30 mg组17例(33%)达到PASI 100。
- 治疗中出现的不良事件:安慰剂组23例(44%),zasocitinib四个剂量组28例(53%)至31例(62%),无剂量依赖性,实验室参数无临床意义的纵向差异。
关键数值与推荐
- 主要疗效终点为第12周达到PASI 75的患者比例。
- 次要疗效终点包括PASI 90和PASI 100应答。
临床怎么用
- zasocitinib 5 mg及以上剂量每日一次可作为中重度斑块状银屑病潜在口服治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: New, effective, and well-tolerated oral therapies are needed for treating psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease. OBJECTIVE: To assess the efficacy, safety, and tolerability of zasocitinib in patients with moderate to severe plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This phase 2b, randomized, double-blind, placebo-controlled, multiple-dose randomized clinical trial was conducted from August 11, 2021, to September 12, 2022, at 47 centers in the US and 8 in Canada. The study included a 12-week treatment period and a 4-week follow-up period. Key eligibility criteria for participants included age 18 to 70 years; a Psoriasis Area and Severity Index (PASI) score of 12 or greater; a Physician's Global Assessment score of 3 or greater; and a body surface area covered by plaque psoriasis of 10% or greater. Of 287 patients randomized, 259 (90.2%) received at least 1 dose of study treatment. INTERVENTION: Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the proportion of patients achieving 75% or greater improvement in PASI score (PASI 75) at week 12. Secondary efficacy end points included PASI 90 and 100 responses. Safety was also assessed. RESULTS: In total, 259 patients were randomized and received treatment (mean [SD] age, 47 [13] years; 82 women [32%]). At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo. PASI 90 responses were consistent with PASI 75. PASI 100 demonstrated a dose response at all doses, with 17 patients (33%) achieving PASI 100 with zasocitinib, 30 mg. Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that potent and selective inhibition of TYK2 with zasocitinib at oral doses of 5 mg or more once daily resulted in greater skin clearance than placebo over 12 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04999839.
引用
- Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 39167366. doi:10.1001/jamadermatol.2024.2701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。